Evaluation of an interchangeability switch in patients treated with clozapine: A retrospective review

Journal of Clinical Psychiatry

Volumn 67, Issue 7, 2006, Pages 1047-1054

  Alessi Severini, Silvia ^a   Honcharik, Patricia L ^a,c   Simpson, Karleen D ^a   Eleff, Michael K ^b   Collins, David M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BEZAFIBRATE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUOXETINE; FLUPENTIXOL; GENERIC DRUG; GLIBENCLAMIDE; LORAZEPAM; METFORMIN; OLANZAPINE; PAROXETINE; PIMOZIDE; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROIC ACID; ZOPICLONE; ZUCLOPENTHIXOL;

ADULT; AGED; BIPOLAR DISORDER; BLOOD DISEASE; BLOOD EXAMINATION; CONSTIPATION; CONTROLLED STUDY; DROWSINESS; DRUG DOSE REGIMEN; EMERGENCY WARD; FEMALE; HANGOVER; HOSPITALIZATION; HUMAN; HYPERSALIVATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MUSCLE SPASM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SALIVATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TOXICITY; TREATMENT FAILURE; TREMOR; UNSPECIFIED SIDE EFFECT;

EID: 33747153580     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0706     Document Type: Review

References (17)

1. Clozaril [package insert]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; 2005
2. Gen-Clozapine [package insert]. Etobicoke, Ontario, Canada: Genpharm Inc; 2003
3. Notice of compliance information: Available at: http://www.hc-sc.gc.ca/ hpfb-dgpsa/tpd-dpt/index_drugs_noc_e.html. Accessibility verified May 12, 2006
4. Expert Advisory Committee on Bioavailability. Report C: Report on Bioavailability of Oral Dosage Formulations, Not in Modified Release Form, of Drugs Used for Systemic Effects, Having Complicated or Variable Pharmacokinetics. December 1992. Available at: http://www. hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guide-Id/bio/biorepc_biorapc_e.html. Accessed Aug 9,2005
5. Draft Guidance Document: Bioequivalence Requirements: Critical Dose Drugs-Scientific Advisory Committee on Unavailability and Bioequivalence (SAC-BB); June 2005. Available at: http://www. hc-sc.gc.ca/dhp-mps/prodpharma/ applic-demande/guide-Id/bio/crit_dose_e.html. Accessed Aug 25, 2005
6. Canada Gazette Part II, Vol. 129, No. 18, September 6, 1995
7. Manitoba Drug Benefits and Interchangeability Formulary Amendments. Bulletin no. 40. Available at: http://www.gov.mb.ca/health/mdbif/bulletin40.pdf. Accessed Aug 9, 2005
8. Manitoba Drug Benefits and Interchangeability Formulary Amendments. Bulletin no. 41. Reminder: Price change for gen-Clozapine. Available at: http://www.gov.mb.ca/health/mdbif/bulletin41.pdf. Accessed Aug 9, 2005
9. Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001;23:1720-1731
10. Kluznik JC, Walbek NH, Farnsworth MG, et al. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001;62(suppl 5):14-17
11. Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001;35:281-284
12. Stoner SC, Lea JW, Dubisa B, et al. A program to convert patients from trade-name to generic clozapine. Pharmacotherapy 2003;23:806-810
13. Tse G, Thompson D, Procyshyn RM. Generic clozapine: a cost saving alternative to brand-name clozapine? Pharmacoeconomics 2003;21:1-11
14. Makela EH, Cutlip WD, Stevenson JM, et al. Branded versus generic clozapine for treatment of schizophrenia. Ann Pharmacother 2003;37:350-353
15. Dettling M, Sachse C, Muller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000;33:218-220
16. Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24:613-617
17. Layton S, Barbeau M. Generic replacement of clozapine: a simple decision model from a Canadian perspective. Curr Med Res Opin 2004;20:453-459